Clinical trials: Sting
Atrial Fibrillation With 2 or 3° AV or Bifascicular Bundle Branch (BBB) Block, Normal Sinus Rhythm With 2 or 3° AV or BBB Block
Evaluation of a New Cardiac Pacemaker
An evaluation of a safety and performance of a new cardiac pacemaker
- Conditions
- Atrial Fibrillation With 2 or 3° AV or Bifascicular Bundle Branch (BBB) Block, Normal Sinus Rhythm With 2 or 3° AV or BBB Block, Sinus Bradycardia With Infrequent Pauses or Unexplained Syncope With EP Findings
- Trial name
- NCT01700244
- Testing
- Pacemaker implant
- Where
- 8 sites in Czechia, Germany and 1 more
- Volunteers
- 36 people
- Sponsor
- Nanostim, Inc.
Snakebite, Envenoming, Snake
Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)
This is a multicenter,randomized,double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability and efficacy of a continuous rate infusion (CRI) of IV varespladib followed by transition to the oral…
- Trial name
- BRAVIO (NCT05717062)
- Testing
- Varespladib intravenous form, varespladib-methyl- oral form
- Where
- 10 sites in United States
- Volunteers
- 140 people
- Sponsor
- Ophirex, Inc.
Atrial Fibrillation, AFib
Stroke Feasibility Study
This is a feasibility study to assess the safety and efficacy of the AtriCure AtriClip when placed via Minimally Invasive Surgical Deployment to the Left Atrial Appendage.
- Trial name
- NCT01997905
- Testing
- AtriClip LAA Exclusion Device
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- AtriCure, Inc.
Snake Bite
Study to Evaluate the Efficacy of Two Treatment Schemes With Antivipmyn ® for the Treatment of Snake Bite Envenomation
The purpose of this study is to compare whether a same total dose given up front as a single dose is more effective and as safe as the same dose given as a fractioned dose.
- Trial name
- NCT00639951
- Testing
- A, Antivipmyn ®
- Where
- 5 sites in Mexico
- Volunteers
- 10 people
- Sponsor
- Instituto Bioclon S.A. de C.V.
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
Insect Bites
Comparative Study of Two Forms of Topical Dexchlorpheniramine Maleate (Cream Versus Gel) for Insect Bites
Insect bite related symptoms (pruritus and papules) are caused by the release of histamine by mast cells in the skin. Topical anti-histaminics can be used to promote relief of these symptoms.
- Trial name
- NCT01233934
- Testing
- Dexchlorpheniramine 1% Gel, Dexchlorpheniramine 1% Cream
- Where
- Brazil
- Volunteers
- 90 people
- Sponsor
- Mantecorp Industria Quimica e Farmaceutica Ltd.
Scorpion Sting Envenomation
Establishment of Natural History of Scorpion Envenomation
This retrospective study was conducted to collect data from approximately 100 patients from 6 months to 18 years of age who were stung by a scorpion but were not treated with antivenom.
- Trial name
- NCT00696683
- Testing
- None, this is an observational study
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Instituto Bioclon S.A. de C.V.
Snake Bites
Safety and Effectiveness of PANAF-Premium TM Snake Venom Antiserum As Standard Treatment for Snakebites
Snakebite envenomation (SBE) is a major public health problem in many developing countries. Standard snake antivenom (SA) remains the primary treatment and has been shown to reduce mortality in observational studies conducted in…
- Trial name
- PMS (NCT06615960)
- Where
- Cameroon
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Premium Serums & Vaccines Pvt.Ltd.
Stenosis, Occlusion
Sequent Please Drug Coated Balloons Versus Primary Stent Application in Long SFA Lesions
Patients with peripheral artery disease will be treated with either drug coated balloon catheter, drug coated stent or uncoated stent.
- Conditions
- Stenosis, Occlusion, Restenosis
- Trial name
- SPORTS (NCT03332264)
- Testing
- SeQuent Please OTW, Eluvia Vascular Stent System, Nitinol stent
- Where
- 10 sites in Austria, Germany
- Volunteers
- 224 people
- Sponsor
- InnoRa GmbH
Scorpion Envenomation
AScVS and/ or Prazosin for Scorpion Envenomation
The data available for the efficacy of AScVS and prazosin is generated through different trials done in different clinical setting.
- Trial name
- NCT00753064
- Testing
- Antiscorpion venom serum(AScVS)., T.Prazosin, AScVS + Prazosin
- Where
- 5 sites in India
- Volunteers
- 81 people
- Sponsor
- Haffkine Bio-Pharmaceutical Corporation Ltd.
Peripheral Artery Disease
Soundbite Crossing System Peripheral First in Man
This is a clinical study aimed at demonstrating the safety and product performance of the SoundBite Crossing System. The study shall demonstrate that the SoundBite Crossing System can facilitate passage of a standard guidewire…
- Trial name
- NCT03013088
- Testing
- CTO Crossing
- Where
- 2 sites in Canada
- Volunteers
- 37 people
- Sponsor
- SoundBite Medical Solutions, Inc.
Arterial Occlusive Disease, Intermittent Claudication
Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries
To obtain additional data on safety and efficacy of the Express stent implantation in the treatment of stenosed or occlusive atherosclerotic disease (de novo or restenotic lesions) in the iliac arteries (common or external).
- Conditions
- Arterial Occlusive Disease, Intermittent Claudication, Atherosclerotic Disease, Thrombosis
- Trial name
- MELODIE (NCT00352222)
- Testing
- stent implantation
- Where
- 10 sites in Belgium, Canada and 3 more
- Volunteers
- 150 people
- Sponsor
- Boston Scientific Corporation
Iliac Artery Occlusive Disease
A Clinical Evaluation of the Bard® Luminexx™ Iliac Stent and Delivery System
To determine the safety and effectiveness of the LUMINEXX stent for the proposed indication of treatment of common and/or external iliac artery occlusive disease
- Trial name
- Luminexx (NCT00561457)
- Testing
- Bard Luminexx Iliac Stent and Delivery System
- Volunteers
- 134 people
- Sponsor
- C. R. Bard
Allergy, Insect Venom, Allergy Insect Stinging
Prospective Observational Study to Evaluate the Safety of Immunotherapy as a Treatment for Hymenoptera Venom Allergy
Observational study to evaluate the safety of immunotherapy as a treatment for Hymenoptera venom allergy, analyzing the adverse reaction to immunotherapy as well as the allergic reaction to a spontaneous hymenoptera sting.
- Conditions
- Allergy, Insect Venom, Allergy Insect Stinging, Insect Sting Allergy
- Trial name
- NCT06782217
- Testing
- VENOX
- Where
- 9 sites in Spain
- Volunteers
- 120 people
- Sponsor
- Inmunotek S.L.
Valve-in-valve Procedures, Aortic Stenosis
The ShortCut™ Continued Access Study Protocol
A Prospective, Multicenter, Non-Randomized, Single-Arm, Open-Label Continued Access Study of the ShortCut™ device (The ShortCut™ CAS).
- Conditions
- Valve-in-valve Procedures, Aortic Stenosis, Coronary; Obstruction
- Trial name
- ShortCut-CAS (NCT06211296)
- Testing
- Shortcut
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Pi-cardia
Insect Bites
Non-inferiority Clinical Trial of Dexchlorpheniramine (Cream Versus Lotion) in the Relief of Insect Bite Related Symptoms
Insect bite related symptoms (pruritus and papules) are caused by the release of histamine by mast cells in the skin. Topical anti-histaminics can be used to promote relief of these symptoms.
- Trial name
- NCT00995397
- Testing
- Dexchlorpheniramine 1% lotion, Dexchlorpheniramine 1% cream
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Mantecorp Industria Quimica e Farmaceutica Ltd.
Snakebites, Envenoming
Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite
This is a multicenter, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability and efficacy of varespladib-methyl, concurrently with standard of care (SOC), in subjects bitten by…
- Conditions
- Snakebites, Envenoming, Envenoming, Snake, Envenomation, Snake
- Trial name
- BRAVO (NCT04996264)
- Testing
- Varespladib Methyl, Standard of care (SOC)
- Where
- 16 sites in United States, India
- Volunteers
- 95 people
- Sponsor
- Ophirex, Inc.
Non-Hodgkin's Lymphoma, Relapsed
Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL
The purpose of this study is to determine whether a continuous infusion of Blinatumomab (MT103) is safe in the treatment of relapsed Non-Hodgkin's Lymphoma.
- Trial name
- NCT00274742
- Testing
- Blinatumomab (MT103)
- Where
- 5 sites in Germany
- Volunteers
- 76 people
- Sponsor
- Amgen Research (Munich) GmbH
Diagnosis, Gonorrhea
Susceptibility Testing In Neisseria Gonorrhoeae (STING) Study, Assessing the Performance of a New Rapid Test for Gonorrhoea Antibiotic Resistance, in a Cohort of 100 Culture Positive Neisseria Gonorrhoeae Infections
This study aims to validate a novel antibiotic susceptibility test (InSignia) for gonorrhoea in patient clinical samples. The hypothesis is that the InSignia test will be able to detect transcriptional responses after incubation…
- Conditions
- Diagnosis, Gonorrhea, Resistance Bacterial
- Trial name
- STING (NCT06352554)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- SpeeDx Pty Ltd
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral…
- Conditions
- Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin
- Trial name
- ON-5001 (NCT06022029)
- Testing
- ONM-501, Cemiplimab
- Where
- 16 sites in United States, Australia
- Volunteers
- 168 people
- Sponsor
- OncoNano Medicine, Inc.